For more information on this report please contact ediz.ibrahim@visiongain.com (+44 (0) 2075499976) or refer to our website: http://www.visiongain.com/Report/1118/Smoking-Cessation-Drugs-World-Market-Prospects-2013-2023

1. ©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision-
gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur-
chase and single copy is for personal use only.
Smoking Cessation Drugs:
World Market Prospects 2013-2023

2. www.visiongain.com
Contents
1.1 Smoking Cessation Drugs: World Market Overview
1.2 Aims and Format of the Report
1.3 Research and Analysis Methods
1.4 Scope of the Report
2.1 Tobacco- What is All the Fuss About?
2.1.1 How is Tobacco Consumed?
2.1.2 Tobacco Smoking is a Major Challenge for Healthcare Worldwide
2.2 Smoking Causes Many Health Disorders
2.3 Nicotine Addiction is at the Root of Smoking
2.4 Smoking Cessation
2.4.1 Why is it Difficult to Stop Smoking?
2.4.2 How Can Smokers Quit?
3.1 How Will the Smoking Cessation Market Develop Until 2023?
3.2 Smoking Cessation Drugs Market by Type of Sale
3.2.1 Over-the-Counter (OTC) Smoking Cessation Drugs, 2012
3.2.1.1 OTC Smoking Cessation Drugs: Forecast, 2013-2023
3.2.2 Prescription (Rx) Smoking Cessation Drugs, 2012
3.2.2.1 Prescription Smoking Cessation Drugs: Forecast, 2013-2023
3.3 Smoking Cessation Drugs by Mechanism of Action
3.3.1 Nicotine Replacement Therapy
3.3.1.1 Nicotine Replacement Therapy, 2012
3.3.1.2 Nicotine Replacement Therapy Forecast, 2013-2023
1. Executive Summary
2. Introduction to Smoking Cessation
3. World Smoking Cessation Drugs Market, 2013-2023

3. www.visiongain.com
Contents
3.3.2 Nicotine Receptor Partial Agonist Drugs
3.3.2.1 Nicotine Receptor Partial Agonist Drugs, 2012
3.3.2.2 Nicotine Receptor Partial Agonist Drugs Forecast, 2013-2023
3.3.3 Antidepressants
3.3.3.1 Antidepressants for Smoking Cessation, 2012
3.3.3.2 Antidepressants for Smoking Cessation: Forecast, 2013-2023
4.1 Major Geographical Markets for the Smoking Cessation Industry in 2012
4.2 The US is Still the Market Leader
4.2.1 Smoking Prevalence Declining in the US
4.2.2 Availability and Reimbursement of Smoking Cessation Aids in the US
4.2.3 US Smoking Cessation Market Revenue, 2012
4.2.4 US Smoking Cessation Market Forecast, 2013-2023
4.2.5 Scope for US Smoking Cessation Market Expansion
4.3 The Japanese Smoking Cessation Market has Potential to Expand in Revenues
4.3.1 Japan has a Less Developed Smoking Cessation Market
4.3.2 The Japanese Smoking Cessation Market, 2012
4.3.3 Japanese Smoking Cessation Market Forecast, 2013-2023
4.4 The EU-5 Smoking Cessation Drugs Market
4.4.1 The UK Smoking Cessation Market
4.4.1.1 Tobacco Use in the UK
4.4.1.2 The UK Pioneers Smoking Cessation Reimbursement and General Sales OTC Retailing
of NRT
4.4.1.3 The UK has Strong Anti-Smoking Legislation
4.4.1.4 UK Smoking Cessation Market, 2012
4.4.1.5 UK Smoking Cessation Market Forecast, 2013-2023
4. Leading National Markets for Smoking Cessation Drugs to 2023

4. www.visiongain.com
Contents
4.4.2 The French Smoking Cessation Market
4.4.2.1 Tobacco Use in France is Still High
4.4.2.2 The French Smoking Cessation Market, 2012
4.4.2.3 French Smoking Cessation Market Forecast, 2013-2023
4.4.2.4 Factors Influencing the Development of the French Market
4.4.3 The Spanish Smoking Cessation Market
4.4.3.1 Tobacco Use in Spain is Low
4.4.3.2 The Spanish Smoking Cessation Market, 2012
4.4.3.3 The Spanish Smoking Cessation Market Forecast, 2013-2023
4.4.3.4 Spain’s Anti-smoking Laws are Very Robust
4.4.4 The Italian Smoking Cessation Market
4.4.4.1 Reducing Tobacco Use in Italy is a Government Priority
4.4.4.2 The Italian Smoking Cessation Market, 2012
4.4.4.3 The Italian Smoking Cessation Market Forecast, 2013-2023
4.4.4.4 Italy has a Decades-Long Commitment to Reducing Smoking
4.4.5 The German Smoking Cessation Market
4.4.5.1 Germany is a Smoker’s Citadel
4.4.5.2 The German Smoking Cessation Market, 2012
4.4.5.3 German Smoking Cessation Market Forecast, 2013-2023
4.4.5.4 Germany Has a Relaxed Attitude to Smoking
4.5 The BRIC Smoking Cessation Drugs Market is Untapped
4.5.1 The Brazilian Smoking Cessation Market
4.5.1.1 Tobacco Use in Brazil is Pervasive
4.5.1.2 The Brazilian Smoking Cessation Market, 2012
4.5.1.3 Brazilian Smoking Cessation Market Forecast, 2013-2023
4.5.1.4 Smoking Cessation Market Prospects in Brazil Look Bright
4.5.2 The Russian Smoking Cessation Market
4.5.2.1 Tobacco Use in Russia Forms a Serious Problem

5. www.visiongain.com
Contents
4.5.2.2 The Russian Smoking Cessation Market, 2012
4.5.2.3 Russian Smoking Cessation Market Forecast, 2013-2023
4.5.2.4 The Russian Government has started to Take Positive Steps
4.5.3 The Indian Smoking Cessation Market: Vast Possibilities
4.5.3.1 India’s Attitudes to Tobacco
4.5.3.2 The Indian Smoking Cessation Market, 2012
4.5.3.3 Indian Smoking Cessation Market Forecast, 2013-2023
4.5.3.4 Indian Smoking Cessation Market Still in its Infancy
4.5.3.5 Prospects for Growth of the Indian Smoking Cessation Market
4.5.4 The Chinese Smoking Cessation Market
4.5.4.1 Tobacco use in China is Unprecedented
4.5.4.2 The Chinese Smoking Cessation Market, 2012
4.5.4.3 Chinese Smoking Cessation Market Forecast, 2013-2023
4.5.4.4 The Chinese Smoking Cessation Market is Under Developed
4.5.4.5 China’s Economic Progress Could be Hindered by Tobacco Use
5.1 The Top 5 Brands Claimed Most of the Market in 2012
5.2 Nicotine Replacement Therapy is a Main Component of the Market
5.2.1 NiQuitin/Nicabate/NicoDerm CQ (GSK)
5.2.2 Nicorette (Johnson & Johnson/GSK)
5.2.3 Nicotinell (Novartis)
5.2.4 Other NRT Products
5.3 Champix/Chantix (Varenicline, Pfizer)
5.3.1 Champix/Chantix Sales Performance, 2012-2023
5.3.2 Champix/Chantix May Help in Treating Other Addictions
5.4 Zyban (Bupropion, GSK)
5. Leading Smoking Cessation Products: Outlook to 2023

6. www.visiongain.com
Contents
5.4.1 Zyban Sales Forecast, 2012-2023
5.5 Tabex – One to Watch Out For
5.6 Other Smoking Cessation Aids
5.6.1 Smokeless Tobacco
5.6.1.1 E-Cigarettes
5.6.1.2 Snus/Snuff
5.6.1.3 Gutkhas
5.6.2 CigRx Dietary Supplement
5.6.3 Dissolvable Tobacco
5.6.4 Behavioural Therapy
6.1 Nicotine Vaccines: Hype or Hope?
6.1.1 TA-Nic (Celtic Pharma)
6.1.2 Niccine (Independent Pharmaceutica AB)
6.1.3 SEL-068 (Selecta Biosciences)
6.2 Monoamine Oxidase Inhibitors
6.3 Cannabinoid Receptor-1 Antagonists
6.4 Dopamine D3 Antagonists
6.5 Opiate Antagonists
6.6 ARD-1600 (Aradigm)
6.7 EMB-001(Embera NeuroTherapeutics)
6.8 Meclizine (Duke University/Philip Morris Products)
6.9 Other Smoking Cessation Aids Under Development
6.9.1 X22
TM
(22
nd
Century Group)
6.9.2 Other Developments
6. Smoking Cessation R&D Pipeline Analysis

7. www.visiongain.com
Contents
7.1 The Smoking Cessation Market was Dominated by Four Companies, But for How Long?
7.2 SWOT and STEP Analysis of the Smoking Cessation Market
7.2.1 Strengths of the Smoking Cessation Industry
7.2.1.1 Innovation in Smoking Cessation Therapies
7.2.1.2 Innovative Marketing
7.2.1.3 Support Plans and Web 2.0 Technology in Combination with Pharmacotherapy
7.2.1.4 OTC Switching
7.2.1.5 Widespread Coverage of Smoking Cessation Products
7.2.2 Weaknesses of the Smoking Cessation Industry
7.2.2.1 Drugs Do Not Replace the Tactile and Oral Sensations Obtained from Smoking
7.2.2.2 Currently-Marketed Smoking Cessation Therapies – Relapse Rate
7.2.2.3 Concerns Regarding the Development of Addiction to NRTs
7.2.3 Opportunities for the Smoking Cessation Industry
7.2.3.1 Smoking is Prevalent Worldwide and Slowly Increasing
7.2.3.2 Countries with Untapped Smoking Cessation Market Potential
7.2.3.3 Growth of Emerging-Economy Smoking Cessation Markets
7.2.3.4 Health Effects of Tobacco
7.2.3.5 Economic and Social Impact of Tobacco on Society
7.2.3.6 Framework Convention on Tobacco Control (FCTC)
7.2.3.7 Government-Sponsored Smoking Cessation Programmes
7.2.3.8 Increasing Tobacco Taxes
7.2.3.9 Smoking Bans
7.2.3.10 Warning Information on Tobacco Products
7.2.3.11 Bans on Tobacco Advertising, Promotion and Sponsorship
7.2.3.12 Upcoming Launch of Tabex
7.2.4 Threats to the Smoking Cessation Industry
7. Smoking Cessation Industry: Qualitative Analyses, 2013-2023

8. www.visiongain.com
Contents
7.2.4.1 Concern over Side-Effects of Smoking Cessation Drugs
7.2.4.2 Lack of Reimbursement for Smoking Cessation Therapies
7.2.4.3 Traditional Smokeless Tobacco
7.2.4.4 The E-Cigarette
8.1 Interview with Dr Vladimir Kosev, Director Strategic Business Development, Sopharma
8.1.1 On Sopharma’s Geographical Focus
8.1.2 On the Availability of Tabex
8.1.3 On the Efficacy of Tabex in Comparison to Other Products
8.1.4 On Any Other Points of Interest
8.2 Interview with Mr Rick Stewart, CEO, Extab Corporation
8.2.1 On Tabex’s Release
8.2.2 On Tabex vs. Other Smoking Cessation Treatments
8.2.3 On the High Prices of Smoking Cessation Products Reducing Revenues in Poorer Nations
8.2.4 On the Future Direction of the Industry
8.2.5 On Any Other Points of Interest
8.3 Interview with Mr Trevor Van Meirlo, CEO, Evolution Health Systems
8.3.1 Unmet Needs
8.3.2 Major Areas of Focus
8.3.3 Smoking Cessation R&D Pipeline
8.3.4 Opportunities for Revenue Growth
8.3.5 Market Drivers
8.4 Interview with Dr Peter Hajek, Director of Tobacco Dependence Research Unit, Wolfson Institute
of Preventive Medicine, Barts and The London School of Medicine and Dentistry, University of
London
8.4.1 Unmet Needs
8. Research Interviews

9. www.visiongain.com
Contents
8.4.2 Major Areas of Focus and R&D Pipeline
8.4.3 Opportunities for Revenue Growth
8.4.4 Market Drivers
9.1 Smoking is the Main Cause of Preventable Deaths Worldwide
9.2 Smoking Cessation Medicines Have Promising Therapeutic and Commercial Potential from 2013
to 2023
9.3 World Smoking Cessation Market: Prospects to 2023
9.4 Market Drivers
9.5 Leading and Emerging Smoking Cessation Markets
9.6 Concluding Remarks
9. Conclusions of the Study

10. www.visiongain.com
Contents
Table 3.1 World Smoking Cessation Market Forecast ($m), 2012-2023
Table 3.2 World Smoking Cessation Market Drivers and Restraints, 2012-2023
Table 3.3 Smoking Cessation Drug Market Forecast ($m) by Type of Sales, 2012-2023
Table 3.4 Over-The-Counter Smoking Cessation Market Forecast ($m), 2012-2023
Table 3.5 OTC Smoking Cessation Market Drivers and Restraints, 2012-2023
Table 3.6 Prescription (Rx) Smoking Cessation Market Forecast ($m), 2012-2023
Table 3.7 Prescription Smoking Cessation Drivers and Restraints, 2012-2023
Table 3.8 Smoking Cessation Market Forecasts by Drug Type ($m), 2012-2023
Table 3.9 Nicotine Replacement Therapy Market Forecast ($m), 2012-2023
Table 3.10 Nicotine Replacement Therapy Drivers and Restraints, 2012-2023
Table 3.11 NRPA Market Forecast ($m), 2012-2023
Table 3.12 NRPA Drivers and Restraints, 2012-2023
Table 3.13 Antidepressants Market Forecast ($m), 2012-2023
Table 3.14 Antidepressants Market Drivers and Restraints, 2012-2023
Table 4.1 Smoking Cessation Drugs Market Forecast ($m) by Leading Countries, 2012-2023
Table 4.2 Smoking Cessation Drugs Market Forecast ($m) & Market Shares (%) by Leading
Countries, 2012
Table 4.3 US Smoking Cessation Drugs Market Forecast ($m), 2012-2023
Table 4.4 US Smoking Cessation Market Drivers and Restraints, 2012-2023
Table 4.5 Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023
Table 4.6 Japanese Smoking Market Cessation Drugs Drivers and Restraints, 2012-2023
Table 4.7 EU5 Smoking Cessation Market Forecasts ($m), 2012-2023
Table 4.8 EU-5 Smoking Cessation Market Drivers and Restraints, 2012-2023
Table 4.9 UK Smoking Cessation Market Forecast ($m), 2012-2023
Table 4.10 French Smoking Cessation Market Forecast ($m), 2012-2023
Table 4.11 Spanish Smoking Cessation Market Forecast ($m), 2012-2023
List of Tables

11. www.visiongain.com
Contents
Table 4.12 Italian Smoking Cessation Market Forecast ($m), 2012-2023
Table 4.13 German Smoking Cessation Market Forecast ($m), 2012-2023
Table 4.14 BRIC Smoking Cessation Market Forecasts ($m), 2012-2023
Table 4.15 BRIC Smoking Cessation Drugs Drivers and Restraints, 2012-2023
Table 4.16 Brazilian Smoking Cessation Market Forecasts ($m), 2012-2023
Table 4.17 Russian Smoking Cessation Market Forecasts ($m), 2012-2023
Table 4.18 Indian Smoking Cessation Market Forecast ($m), 2012-2023
Table 4.19 Chinese Smoking Cessation Market Forecast ($m), 2012-2023
Table 5.1 Top 5 Smoking Cessation Drugs’ Sales ($m) and Market Shares (%), 2012
Table 5.2 Leading Smoking Cessation Brands: Sales Forecasts ($m), 2012-2023
Table 5.3 Nicotine Replacement Therapy Types, 2012
Table 5.4 NiQuitin /Nicabate/NicoDerm CQ NRT Brands, 2012
Table 5.5 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023
Table 5.6 NiQuitin/Nicabate/NicoDerm CQ Drivers and Restraints, 2012-2023
Table 5.7 Nicorette NRT Brands, 2012
Table 5.8 Nicorette Sales Forecast ($m), 2012-2023
Table 5.9 Nicorette Drivers and Restraints, 2012-2023
Table 5.10 Nicotinell Sales Forecast ($m), 2012-2023
Table 5.11 Nicotinell Drivers and Restraints, 2012-2023
Table 5.12 Champix/Chantix Sales Forecast ($m), 2012-2023
Table 5.13 Champix/Chantix Drivers and Restraints, 2012-2023
Table 5.14 Zyban Sales Forecast ($m), 2012-2023
Table 5.15 Zyban Drivers and Restraints 2012-2023
Table 5.16 Tabex Sales Forecast ($m), 2012-2023
Table 5.17 Tabex Drivers and Restraints, 2012-2023
Table 6.1 Smoking Cessation R&D Pipeline: Some Leading Product Candidates, 2013
Table 6.2 Smoking Cessation R&D Pipeline: Apparent Disappointments

12. www.visiongain.com
Contents
Table 7.1 Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and
Market Share (%), 2012
Table 7.2 Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and
Market Share (%), 2023
Table 7.3 Other Companies Operating in the Smoking Cessation Industry
Table 7.4 SWOT Analysis of the Industry and Market, 2012-2023
Table 7.5 STEP Analysis of the Industry and Market, 2012-2023
Table 9.1 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by OTC and Rx,
2013, 2017 & 2023
Table 9.2 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Drug Type,
2013, 2017 & 2023
Table 9.3 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Leading
Countries, 2013, 2017 & 2023

13. www.visiongain.com
Contents
Figure 2.1 Smoking-Related Health Disorders
Figure 3.1 World Smoking Cessation Market Forecast ($m), 2012-2023
Figure 3.2 Smoking Cessation Market Shares (%) by Type of Sale, 2012
Figure 3.3 OTC Smoking Cessation Drugs Market Forecast ($m), 2012-2023
Figure 3.4 Rx Smoking Cessation Market Forecast ($m), 2012-2023
Figure 3.5 Smoking Cessation Market Shares (%) by Drug Type, 2012
Figure 3.6 NRT Market Forecast ($m), 2012-2023
Figure 3.7 NRPA Market Forecast ($m), 2012-2023
Figure 3.8 Antidepressants for Smoking Cessation: Market Forecast ($m), 2012-2023
Figure 4.1 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2012
Figure 4.2 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2017
Figure 4.3 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2023
Figure 4.4 US Smoking Cessation Drugs Market Forecast ($m), 2012-2023
Figure 4.5 Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023
Figure 4.6 EU5 Smoking Cessation Market Forecasts ($m), 2012-2023
Figure 4.7 UK Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.8 French Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.9 Spanish Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.10 Italian Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.11 German Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.12 BRIC Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.13 Brazilian Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.14 Russian Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.15 Indian Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.16 Chinese Smoking Cessation Market Forecast ($m), 2012-2023
List of Figures

14. www.visiongain.com
Contents
Figure 5.1 Top 5 Smoking Cessation Drugs: Market Shares (%), 2012
Figure 5.2 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023
Figure 5.3 Nicorette Sales Forecast ($m), 2012-2023
Figure 5.4 Nicotinell Sales Forecast ($m), 2012-2023
Figure 5.5 Champix/Chantix Sales Forecast ($m), 2012-2023
Figure 5.6 Zyban Sales Forecast ($m), 2012-2023
Figure 5.7 Tabex Sales Forecast ($m), 2012-2023
Figure 7.1 Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2012
Figure 7.2 Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2023
Figure 9.1 Smoking Cessation Drugs: World Market Revenue Forecast ($m), 2012-2023
Figure 9.2 Smoking Cessation Drug Market by Leading Countries: Market Shares (%), 2013, 2017 &
2023

15. www.visiongain.com
Contents
22
nd
Century Group
Action on Smoking on Health (ASH)
Advent Life Sciences
Alkermes
American Heart Association (AHA)
American Lung Association (ALA)
Aradigm
Australian Therapeutic Goods Administration
BGP Group
Boots
Cochrane Collaboration
Cambrex
Campaign for Tobacco-Free Kids
Cancer Centre and Institute of Oncology
Ceejay Healthcare
Celtic Pharma
Centers for Disease Control and Prevention (CDC)
Cephalon
China National Tobacco Corporation
CN Creative
Cytos Biotechnology
Duke University
Embera NeuroTherapeutics
European Medicines Agency (EMA)
Evolution Health Systems
Evotec
Organisations Mentioned

16. www.visiongain.com
Contents
Excelsa Pharma
Extab Corporation
Fertin Pharma A/S
Food and Drug Administration (US FDA)
GlaxoSmithKline (GSK)
Haihang Industry Company
Health Canada
Independent Pharmaceutica AB
Japanese Ministry of Health, Labour and Welfare (MHLW)
Japan Tobacco
Johnson & Johnson
Karolinska Institutet
LEO Pharma
LSU Health Sciences Center – Shreveport
Mayo Clinic
Medicines and Healthcare Products Regulatory Agency (MHRA)
Nabi Biopharmaceuticals
National Cancer Institute (NCI)
National Health Service (UK NHS)
National Institute for Health and Clinical Excellence (UK NICE)
National Institute on Drug Abuse (NIDA)
Next Safety
Nicobrand
Niconovum AB
Nicoventures
Novartis
Nulife
Nu-Mark

17. www.visiongain.com
Contents
Perrigo
Pfizer
Philip Morris Products S.A
Queen Mary University of London
Revolymer
R.J. Reynolds Tobacco Company
Rock Creek Pharmaceuticals
Roche
Ruyan
Sanofi
Selecta Biosciences
Sopharma
Spanish Ministry of Health, Social Services and Equality
Star Scientific
Taj Pharmaceuticals
Target Corporation
Teva Pharmaceutical Industries
Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The
London School of Medicine and Dentistry
Tobacco Manufacturers Association
University College London (UCL)
UK Centre for Tobacco Control Studies
Walmart
Wolfson Institute of Preventive Medicine
World Bank
World Health Organization (WHO)
Zenara

18. Page 54www.visiongain.com
Smoking Cessation Drugs: World
Market Prospects 2013-2023
• Sublingual tablets.
Other NRT products are sold only at pharmacies and include the following:
• Inhalers
• Nasal spray.
In 2008, the Medicines and Healthcare products Regulatory Agency (MHRA) considered proposals
to end restricting sales of inhalers and nasal spray to pharmacies. This has led to availability of
these NRT products in other retail outlets, in addition to pharmacies.
4.4.1.3 The UK has Strong Anti-Smoking Legislation
A ban on smoking in public places in the UK lifted the UK smoking cessation market by 2009.
Currently, the UK is the largest European smoking cessation market and the second-largest in the
world. The UK Government has been active in discouraging smoking in recent years. Smoking
cessation products have been reimbursed by the NHS since 2001. In addition, since October 2007
it has become illegal in the UK to sell tobacco to people under the age of 18 (previously it was 16).
All forms of tobacco advertising have also been banned, and there is a virtual blanket ban on
smoking in all enclosed public spaces, such as offices and restaurants. All of these measures are
helping to reduce the prevalence of smoking in the UK, and visiongain expects this to, in turn,
provide a boost to the smoking cessation drug market in the UK over the forecast period.
4.4.1.4 UK Smoking Cessation Market, 2012
In 2012, the UK smoking cessation market was worth $177m, and this represents an increase of
1.31% over the previous year’s revenue figure of $174m
4.4.1.5 UK Smoking Cessation Market Forecast, 2013-2023
The UK smoking-cessation market is the largest in Europe and the government has been vigorous
in introducing bans on smoking and promoting smoking cessation plans and products. Visiongain
therefore believes that the market for smoking cessation drugs market will grow moderately from
2013 to 2023. The UK Government's strong anti-smoking agenda, including its willingness to
reimburse smoking cessation products, will provide a strong impetus for smokers to stop smoking.
This will lead to increased sales of smoking cessation products, visiongain concludes.

19. Page 55www.visiongain.com
Smoking Cessation Drugs: World
Market Prospects 2013-2023
The general public in the UK is aware of the dangerous effects of smoking and the availability of
smoking cessation products. Visiongain predicts that the UK smoking cessation market will
therefore show increasing growth rate at a modest pace. Starting at a value of $179m in 2013, by
2017, the size of the UK market will have increased to $209m at a CAGR of 3.89%. Moreover, by
2023, the market size would have increased to $289m, at a CAGR of 4.89%.
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
UK ($m) 174 177 179 184 190 199 209 221 235 249 264 277 289
Annual Growth (%) 1.31 1.68 2.57 3.40 4.31 5.29 5.91 6.07 6.16 5.75 5.04 4.47
CAGR (%, from 2013) 3.89 4.89
4.4.2 The French Smoking Cessation Market
4.4.2.1 Tobacco Use in France is Still High
There are an estimated 15 million tobacco smokers in France, representing a national prevalence
of 29% among people aged 15 years or older (35% among men and 23% among women).
Smoking prevalence has remained fairly stable in the last five years and does not appear to have
been greatly affected by the ban on smoking in pubic places, which began on 1st January 2007.
0
50
100
150
200
250
300
350
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
UKRevenues($m)
Year
Source: visiongain 2013
Table 4.9 UK Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.7 UK Smoking Cessation Market Forecast ($m), 2012-2023
Source: visiongain 2013